Added to YB: 2025-01-23
Pitch date: 2024-12-06
ACE.ST [bullish]
Ascelia Pharma AB (publ)
-73.16%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden.
Market Cap
SEK 107.9M
Pitch Price
SEK 3.01
Price Target
N/A
Dividend
N/A
EV/EBITDA
-1.07
P/E
-1.38
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
Show full summary:
Ascelia Pharma AB - $ACE.ST
ACE.ST: Orviglance liver MRI agent for renal patients completed Phase III, FDA submission mid-2025. $800M global market, no competitors, 80% margins. Undervalued at $26M cap ($7.5M cash). Strong M&A potential in radiopharmaceuticals. Key catalysts: commercialization partner, FDA approval.
Read full article (32 min)